Alexion Pharmaceuticals Soliris NDA for PNH receives approval in Japan Alexion Pharmaceuticals.

Soliris received orphan medication designation from the MHLW in ’09 2009 and was accepted under the Ministry’s priority review process.D., CEO of Alexion. ‘This regulatory approval marks another essential step in our global commitment to the objective of providing usage of Soliris to all or any patients who can benefit from it. We now anticipate working carefully with the healthcare authorities in Japan to create Soliris open to patients as rapidly as possible.’ Related StoriesHealthcare technology sociable event of the year opens entriesAddressing quality of life needs in prostate cancer: an interview with Professor Louis DenisAmgen announces submission of supplemental New Medication Program to FDA for Kyprolis Soliris was accepted as cure for sufferers with PNH by the U.S.Hands-On Workshop: Wound Closure. Hosted by Lee C. Rogers, DPM, and Nicholas J. Bevilacqua, DPM, Associate Medical Directors of the Amputation Prevention Center at Valley Presbyterian Hospital in Van Nuys, Calif., saturday the workshop will become held, March 20, from 7 a.m. To 10 a.m. In the Hollywood Ballroom Studio D. At the workshop, pieces of Dermagraft will be available for attendees to apply preparing and deciding on a rubber foot ulcer wound. To date, nearly 200,000 bits of Dermagraft have been supplied to over 1,000 wound care outpatient and centers clinics nationwide.